Clinical trials: sponsored by University of Calgary
Sarcoma, Giant Cell Tumor of Bone
Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients
Sarcoma is a rare form of bone and soft tissue cancer, making up about 1% of all adult cancers. Management typically involves radiation therapy, chemotherapy, and surgical resection.
- Trial name
- NCT07227961
- Testing
- Surgery
- Where
- 4 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- University of Calgary
Ureteropelvic Junction Obstruction, Hypospadias
Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children
The goal of this clinical trial is to determine whether giving oxybutynin before urologic reconstruction surgery reduces the amount of opioid pain medication needed in children.
- Trial name
- NCT07911137
- Testing
- Oxybutynin
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University of Calgary
Gait Balance
EVS With Exercise for Balance With Older Adults
This study will test whether electrical stimulation of the balance system adds benefit to an exercise program for adults aged 60 years and older. The treatment is called noisy electrical vestibular stimulation (nEVS).
- Trial name
- NCT07890623
- Testing
- Noisy electrical vestibular stimulation
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
The ascending aorta conducts blood from the heart to the rest of the body. The ascending aorta can become enlarged, and the risk of tearing and rupturing becomes higher with larger aorta.
- Trial name
- TITAN:SvS (NCT03536312)
- Testing
- Thoracic Aortic Surgery
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 610 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Stroke, Acute Ischemic, Medium Vessel Occlusion
INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of IMP-ACT. Acute ischemic stroke (AIS) caused by intracranial arterial occlusion remains a major cause of disability and…
- Trial name
- IMP-ACT (NCT07906275)
- Testing
- Mechanical Endovascular Thrombectomy, Intravenous Thrombolysis, Tenecteplase/Alteplase- depending upon availability at each treating centre
- Where
- 4 sites in Canada
- Volunteers
- 800 people
- Sponsor
- University of Calgary
Attention-Deficit/ Hyperactivity Disorder (ADHD)
Pharmacogenomics of Stimulant Treatment Response
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity…
- Trial name
- PGx-STaR (NCT06221358)
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of Calgary
Delirium, Intensive Care Unit Delirium
Family-partnered Delirium Prevention, Detection, and Management in the ICU
Almost half of critically ill patients experience delirium. Delirium is associated with impaired cognition, mortality, and increased healthcare costs.
- Conditions
- Delirium, Intensive Care Unit Delirium, Post Intensive Care Unit Syndrome, Post Intensive Care Unit Syndrome Family
- Trial name
- ACTIVATE (NCT07896356)
- Testing
- Standard of Care, Delirium Education, Prevention, and Management
- Where
- Canada
- Volunteers
- 1,344 people
- Sponsor
- University of Calgary
Crohn Disease
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor [TNF] alpha, anti-integrin, and anti-interleukin [IL]-23 targeted…
- Trial name
- PATHFINDER (NCT05928039)
- Testing
- TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab
- Where
- 23 sites in Canada
- Volunteers
- 210 people
- Sponsor
- University of Calgary
Acute Ischemic Stroke AIS, Stroke Acute
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design.
- Conditions
- Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic
- Trial name
- ACT-WHEN (NCT06320431)
- Testing
- Tenecteplase
- Where
- 24 sites in Australia, Canada
- Volunteers
- 4,000 people
- Sponsor
- University of Calgary
Stroke, Acute Ischemic, Endovascular Thrombectomy
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Study Design and Duration: This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT.
- Conditions
- Stroke, Acute Ischemic, Endovascular Thrombectomy, Acute Ischemic Stroke AIS
- Trial name
- ACT-REACT (NCT07687056)
- Testing
- Tenecteplase or Alteplase- depending upon availability at each treating centre, Control
- Where
- 13 sites in Australia, Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Calgary
Microscopic Colitis
Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis
The purpose of this research study is to compare how well two formulations of budesonide (budesonide MMX [Cortiment] and budesonide CR [Entocort]) work for treating patients with microscopic colitis.
- Trial name
- NCT05915104
- Testing
- Budesonide MMX®, Budesonide controlled ileal release (CR) capsules
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- University of Calgary
Irritable Bowel Syndrome (IBS), Microbiome
SIMBA in Irritable Bowel Syndrome (IBS)
This study is intended to characterize longitudinal changes in the small intestinal microbiome following rifaximin treatment in participants with Irritable Bowel Syndrome (IBS) over a 12 week period.
- Trial name
- SIMPACT (NCT07882953)
- Testing
- Rifaximin (drug), fluid biopsy capsule
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- University of Calgary
Ehlers-Danlos Syndrome, Anesthesia, Local
Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers
Local anesthetic resistance is commonly reported by patients with EDS. However, there are no objective data on the occurrence of local anesthetic resistance in EDS patients and in healthy volunteers.
- Trial name
- NCT04036305
- Testing
- 0.9% Sodium Chloride Injection, Lidocaine Injection 2%, Bupivacaine Injection 0.5%
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Postural Tachycardia Syndrome
POTS NET mRNA Functional Correlation With NET Activity
DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal…
- Trial name
- NCT03218761
- Testing
- NET mRNA level, Plasma catechols, Urine Catechols
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what…
- Conditions
- Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT07297667
- Testing
- Fludarabine, Cyclophosphamide, GCAR1
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
Motility Disorder, Gastroparesis
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
This is an analytical validation observational cohort study is designed to provide evidence of: safety and reliability of Body Surface Gastric Mapping using the Gastric Alimetry System (GAS), normal reference values, and…
- Conditions
- Motility Disorder, Gastroparesis, Functional Dyspepsia, Cyclical Vomiting
- Trial name
- NCT05812339
- Testing
- Gastric Alimetry System
- Where
- Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Obsessive Compulsive Disorder (OCD)
Low-intensity Ultrasound for Individuals With Obsessive-compulsive Disorder
The goal of this clinical trial is to learn whether low-intensity focused ultrasound (LIFU), a non-invasive form of brain stimulation, can change brain activity and improve thinking and decision-making in adults with…
- Trial name
- LIFU-OCD (NCT07872917)
- Testing
- Low-intensity focused ultrasound (Active)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
Clinical Performance of ComBatic™ Antimicrobial Wound Care Products in Hard-to-Heal Wounds
The goal of this clinical trial is To assess the feasibility of delivering the study protocol in adults with chronic, hard-to-heal lower leg wounds.
- Trial name
- COMBAT-H (NCT07872930)
- Testing
- Irrigation Solution for wounds, Hydrogel for wound care
- Volunteers
- 96 people
- Sponsor
- University of Calgary
Urinary Incontinence, Overactive Bladder Syndrome
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with…
- Conditions
- Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
- Trial name
- NCT05878951
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Northwestern University
Hip Fractures
HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot)
As our Canadian population ages, hip fractures in these older adults are becoming very common. The best treatment for the majority of these injuries is urgent treatment with surgery.
- Trial name
- HIP PRO Pilot (NCT05775965)
- Testing
- Rivaroxaban 10mg, acetylsalicylic acid (ASA) 81mg Oral Tablet
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- University of Calgary